<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02829996</url>
  </required_header>
  <id_info>
    <org_study_id>IPC-02-2015</org_study_id>
    <nct_id>NCT02829996</nct_id>
  </id_info>
  <brief_title>Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG</brief_title>
  <official_title>Phase II, Randomized, Double-masked, Active-controlled Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Subjects With Ocular Hypertension or Primary Open-Angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inotek Pharmaceuticals Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inotek Pharmaceuticals Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II, randomized, double-masked study to evaluate the efficacy and tolerability of
      topical ocular delivery of fixed-dosed combinations of trabodenoson and latanoprost in
      subjects with Ocular Hypertension or Primary Open-Angle Glaucoma.

      All subjects who meet the study's enrollment criteria following Screening will undergo
      washout of all prohibited medications (if washout is needed), including their routine
      glaucoma medications. During the Placebo Run-In Period, placebo is applied twice daily to
      both eyes in all subjects. During the Treatment Period, study drug is applied to both eyes
      for a total of 8 weeks. Each subject will be assigned 4 weeks of AM and 4 weeks of PM dosing
      in a masked manner. AM vs PM dosing is masked utilizing Placebo in addition to the active
      drug product. During the Treatment Period, study drug (Active and Placebo) eye drop
      applications will occur twice daily, in the morning and in the evening. The Treatment Period
      will be followed by an Observation Period of approximately 7 days wherein no study eye drops
      are instilled.

      The purpose of the study is to assess the overall benefit/risk profile of binocular topical
      application of different doses of trabodenoson (3.0% and 6.0%) when combined with latanoprost
      (0.005% or 0.0025%) one drop daily (QD) for 8 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II, randomized, double-masked study to evaluate the efficacy and tolerability
      of topical ocular delivery of fixed-dose combinations of trabodenoson and latanoprost in
      subjects with OHT or POAG.

      The Primary Objective of this Trial is to evaluate the efficacy of different topical ocular
      doses of trabodenoson (3.0% and 6.0%) when added to latanoprost (0.005% or 0.0025%), one drop
      daily to both eyes over two consecutive 4 week periods. The Secondary Objective is to
      evaluate the tolerability and safety of different doses of trabodenoson (3.0% and 6.0%) when
      added to latanoprost (0.005% or 0.0025%), one drop daily to both eyes over two consecutive 4
      week periods. the Hypotheses is that topical ocular co-administration of 3.0% or 6.0%
      trabodenoson plus latanoprost 0.0025% or 0.005% ophthalmic formulation will reduce IOP and be
      well-tolerated.

      All subjects who meet the study's enrollment criteria following Screening will undergo
      washout of all prohibited medications, including their routine glaucoma medications. During
      the Placebo Run-In Period, placebo (vehicle control matched to trabodenoson) is applied twice
      daily to both eyes in all subjects. During the Treatment Period, study drug is applied to
      both eyes for a total of 8 weeks. Each subject will be assigned 4 weeks of AM and 4 weeks of
      PM dosing in a manner that is masked to the patient. The Treatment Period will be followed by
      an Observation Period of approximately 7 days wherein no study eye drops are instilled.

      To mimic what is generally seen in clinical trials, the number of subjects with ocular
      hypertension as their diagnosis will be limited to approximately 30% of the total subjects
      enrolled. Additionally, so the trial mirrors the general population demographics (so as to
      improve generalizability of the results) the proportion of African American subjects will be
      approximately 25% or less but not less than 12% of the total subjects enrolled.

      The purpose of the study is to assess the efficacy, tolerability, and safety of binocular
      topical application of different doses of trabodenoson (3.0% and 6.0%) when added to
      latanoprost (0.005% or 0.0025%) one drop daily over two consecutive 4 week periods in
      subjects with POAG or OHT. Data collection will include efficacy (masked-IOPs), local
      (ophthalmic) and systemic tolerability and safety assessments
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 19, 2016</start_date>
  <completion_date type="Actual">May 31, 2017</completion_date>
  <primary_completion_date type="Actual">May 24, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Intraocular Pressure (IOP)</measure>
    <time_frame>Two Months</time_frame>
    <description>Daily change from diurnal baseline in IOP</description>
  </primary_outcome>
  <other_outcome>
    <measure>Safety Parameters, Including Treatment Emergent Adverse Events, to Assess Tolerability and Safety.</measure>
    <time_frame>Through Study Completion, up to 9 weeks.</time_frame>
    <description>Collection of safety parameters, including treatment emergent adverse events, laboratory assessments, to assess tolerability and safety.</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">201</enrollment>
  <condition>Primary Open-Angle Glaucoma (POAG)</condition>
  <condition>Ocular Hypertension (OHT)</condition>
  <arm_group>
    <arm_group_label>trabodenoson 6.0% /latanoprost 0.005% QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>trabodenoson 6.0% / latanoprost 0.005% QD FDC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>trabodenoson 3.0% /latanoprost 0.005% QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>trabodenoson 3.0% / latanoprost 0.005% QD FDC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>trabodenoson 6.0% /latanoprost 0.0025%QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>trabodenoson 6.0% /latanoprost 0.0025% QD FDC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>latanoprost 0.005% QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>latanoprost 0.005% ophthalmic solution QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>latanoprost 0.0025% QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>latanoprost 0.0025% ophthalmic solution QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trabodenoson 6.0% / latanoprost 0.005% QD</intervention_name>
    <description>Trabodenoson 6.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.</description>
    <arm_group_label>trabodenoson 6.0% /latanoprost 0.005% QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trabodenoson 3.0% / latanoprost 0.005% QD</intervention_name>
    <description>Trabodenoson 3.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.</description>
    <arm_group_label>trabodenoson 3.0% /latanoprost 0.005% QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trabodenoson 6.0% / latanoprost 0.0025% QD</intervention_name>
    <description>Trabodenoson 6.0% / latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.</description>
    <arm_group_label>trabodenoson 6.0% /latanoprost 0.0025%QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>latanoprost 0.005% QD</intervention_name>
    <description>Latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.</description>
    <arm_group_label>latanoprost 0.005% QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>latanoprost 0.0025% QD</intervention_name>
    <description>Latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.</description>
    <arm_group_label>latanoprost 0.0025% QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of ocular hypertension (OHT) or primary open-angle glaucoma (POAG)

          -  Mean Intraocular pressure (IOP) of ≥25 and ≤34

        Exclusion Criteria:

          -  Significant visual field loss or any new field loss within the past year

          -  Cup-to-disc ratio &gt;0.8

          -  Central corneal thickness &lt;490 µm or &gt;610 µm

          -  A recent (acute) or chronic medical condition that might obfuscate the Subject's study
             data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cadmus C Rich, MD,MBA,CPE</last_name>
    <role>Study Director</role>
    <affiliation>Inotek Pharmaceuticals Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inotek Pharmaceuticals Corporation</name>
      <address>
        <city>Lexington</city>
        <state>Massachusetts</state>
        <zip>02421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2016</study_first_submitted>
  <study_first_submitted_qc>July 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2016</study_first_posted>
  <results_first_submitted>November 28, 2017</results_first_submitted>
  <results_first_submitted_qc>January 19, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 15, 2018</results_first_posted>
  <last_update_submitted>January 19, 2018</last_update_submitted>
  <last_update_submitted_qc>January 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <keyword>primary open-angle glaucoma</keyword>
  <keyword>ocular hypertension</keyword>
  <keyword>adenosine agonist</keyword>
  <keyword>eye drop</keyword>
  <keyword>trabodenoson</keyword>
  <keyword>trabecular meshwork</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Trabodenoson 6.0% / Latanoprost 0.005% QD</title>
          <description>trabodenoson 6.0% / latanoprost 0.005% Fixed-Dose Combination
trabodenoson 6.0% / latanoprost 0.005% QD: Trabodenoson 6.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Trabodenoson 3.0% / Latanoprost 0.005% QD</title>
          <description>trabodenoson 3.0% / latanoprost 0.005% Fixed-Dose Combination
trabodenoson 3.0% / latanoprost 0.005% QD: Trabodenoson 3.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Trabodenoson 6.0% / Latanoprost 0.0025% QD</title>
          <description>trabodenoson 6.0% / latanoprost 0.0025% Fixed-Dose Combination
trabodenoson 6.0% / latanoprost 0.0025% QD: Trabodenoson 6.0% / latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Latanoprost 0.005% QD</title>
          <description>latanoprost 0.005% ophthalmic solution
latanoprost 0.005% QD: Latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Latanoprost 0.0025% QD</title>
          <description>latanoprost 0.0025% ophthalmic solution
latanoprost 0.0025% QD: Latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="41"/>
                <participants group_id="P5" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="41"/>
                <participants group_id="P5" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Trabodenoson 6.0% / Latanoprost 0.005% QD</title>
          <description>trabodenoson 6.0% / latanoprost 0.005% Fixed-Dose Combination
trabodenoson 6.0% / latanoprost 0.005% QD: Trabodenoson 6.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Trabodenoson 3.0% / Latanoprost 0.005% QD</title>
          <description>trabodenoson 3.0% / latanoprost 0.005% Fixed-Dose Combination
trabodenoson 3.0% / latanoprost 0.005% QD: Trabodenoson 3.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Trabodenoson 6.0% / Latanoprost 0.0025% QD</title>
          <description>trabodenoson 6.0% / latanoprost 0.0025% Fixed-Dose Combination
trabodenoson 6.0% / latanoprost 0.0025% QD: Trabodenoson 6.0% / latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Latanoprost 0.005% QD</title>
          <description>latanoprost 0.005% ophthalmic solution
latanoprost 0.005% QD: Latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Latanoprost 0.0025% QD</title>
          <description>latanoprost 0.0025% ophthalmic solution
latanoprost 0.0025% QD: Latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="39"/>
            <count group_id="B3" value="40"/>
            <count group_id="B4" value="41"/>
            <count group_id="B5" value="42"/>
            <count group_id="B6" value="201"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.1" spread="12.08"/>
                    <measurement group_id="B2" value="64.4" spread="9.18"/>
                    <measurement group_id="B3" value="68.8" spread="8.43"/>
                    <measurement group_id="B4" value="66.5" spread="9.84"/>
                    <measurement group_id="B5" value="66.4" spread="8.57"/>
                    <measurement group_id="B6" value="66.0" spread="9.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="27"/>
                    <measurement group_id="B6" value="108"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="32"/>
                    <measurement group_id="B6" value="152"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="42"/>
                    <measurement group_id="B6" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline IOP</title>
          <description>mm of mercury on Goldmann Applanation Tonometry</description>
          <units>mm of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.67" spread="2.329"/>
                    <measurement group_id="B2" value="27.17" spread="2.278"/>
                    <measurement group_id="B3" value="27.28" spread="2.155"/>
                    <measurement group_id="B4" value="27.48" spread="2.627"/>
                    <measurement group_id="B5" value="27.31" spread="2.276"/>
                    <measurement group_id="B6" value="27.38" spread="2.323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Intraocular Pressure (IOP)</title>
        <description>Daily change from diurnal baseline in IOP</description>
        <time_frame>Two Months</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Trabodenoson 6.0% / Latanoprost 0.005% QD</title>
            <description>trabodenoson 6.0% / latanoprost 0.005% Fixed-Dose Combination
trabodenoson 6.0% / latanoprost 0.005% QD: Trabodenoson 6.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Trabodenoson 3.0% / Latanoprost 0.005% QD</title>
            <description>trabodenoson 3.0% / latanoprost 0.005% Fixed-Dose Combination
trabodenoson 3.0% / latanoprost 0.005% QD: Trabodenoson 3.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Trabodenoson 6.0% / Latanoprost 0.0025% QD</title>
            <description>trabodenoson 6.0% / latanoprost 0.0025% Fixed-Dose Combination
trabodenoson 6.0% / latanoprost 0.0025% QD: Trabodenoson 6.0% / latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Latanoprost 0.005% QD</title>
            <description>latanoprost 0.005% ophthalmic solution
latanoprost 0.005% QD: Latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Latanoprost 0.0025% QD</title>
            <description>latanoprost 0.0025% ophthalmic solution
latanoprost 0.0025% QD: Latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Intraocular Pressure (IOP)</title>
          <description>Daily change from diurnal baseline in IOP</description>
          <population>Intent to treat</population>
          <units>mm of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.4" spread="0.48"/>
                    <measurement group_id="O2" value="-6.8" spread="0.56"/>
                    <measurement group_id="O3" value="-6.4" spread="0.56"/>
                    <measurement group_id="O4" value="-7.1" spread="0.46"/>
                    <measurement group_id="O5" value="-5.9" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Safety Parameters, Including Treatment Emergent Adverse Events, to Assess Tolerability and Safety.</title>
        <description>Collection of safety parameters, including treatment emergent adverse events, laboratory assessments, to assess tolerability and safety.</description>
        <time_frame>Through Study Completion, up to 9 weeks.</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>9 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Trabodenoson 6.0% / Latanoprost 0.005% QD</title>
          <description>trabodenoson 6.0% / latanoprost 0.005% Fixed-Dose Combination
trabodenoson 6.0% / latanoprost 0.005% QD: Trabodenoson 6.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Trabodenoson 3.0% / Latanoprost 0.005% QD</title>
          <description>trabodenoson 3.0% / latanoprost 0.005% Fixed-Dose Combination
trabodenoson 3.0% / latanoprost 0.005% QD: Trabodenoson 3.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Trabodenoson 6.0% / Latanoprost 0.0025% QD</title>
          <description>trabodenoson 6.0% / latanoprost 0.0025% Fixed-Dose Combination
trabodenoson 6.0% / latanoprost 0.0025% QD: Trabodenoson 6.0% / latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Latanoprost 0.005% QD</title>
          <description>latanoprost 0.005% ophthalmic solution
latanoprost 0.005% QD: Latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Latanoprost 0.0025% QD</title>
          <description>latanoprost 0.0025% ophthalmic solution
latanoprost 0.0025% QD: Latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Discharge</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Conjunctival Hyperaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Punctate Keratitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>UTI</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Roni Cohen</name_or_title>
      <organization>Inotek Pharmaceuticals Corp.</organization>
      <phone>781-676-2100</phone>
      <email>rcohen@inotekpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

